Literature DB >> 15187156

Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma.

Sergey Ryzhov1, Anna E Goldstein, Anton Matafonov, Dewan Zeng, Italo Biaggioni, Igor Feoktistov.   

Abstract

Adenosine provokes bronchoconstriction in asthmatics through acute activation of mast cells, but its potential role in chronic inflammation has not been adequately characterized. We hypothesized that adenosine up-regulates Th2 cytokines in mast cells, thus promoting IgE synthesis by B lymphocytes. We tested this hypothesis in human mast cells (HMC-1) expressing A(2A), A(2B), and A(3) adenosine receptors. The adenosine analog 5'-N-ethylcarboxamidoadenosine (NECA) (10 microM) increased mRNA expression of IL-1beta, IL-3, IL-4, IL-8, and IL-13, but not IL-2 and IFN-gamma. Up-regulation of IL-4 and IL-13 was verified using RT-PCR and ELISA; 10 microM NECA increased IL-13 concentrations in HMC-1 conditioned medium 28-fold, from 7.6 +/- 0.3 to 215 +/- 4 pg/ml, and increased IL-4 concentrations 6-fold, from 19.2 +/- 0.1 to 117 +/- 2 pg/ml. This effect was mediated by A(2B) receptors because neither the selective A(2A) agonist 2-p-(2-carboxyethyl)phenethylamino-NECA nor the selective A(3) agonist N(6)-(3-iodobenzyl)-N-methyl-5'-carbamoyladenosine reproduced it, and the selective A(2B) antagonist 3-isobutyl-8-pyrrolidinoxanthine prevented it. Constitutive expression of CD40 ligand on HMC-1 surface was not altered by NECA. Human B lymphocytes cocultured for 12 days with NECA-stimulated HMC-1 produced 870 +/- 33 pg IgE per 10(6) B cells, whereas lymphocytes cocultured with nonstimulated HMC-1, or cultured alone in the absence or in the presence of NECA, produced no IgE. Thus, we demonstrated induction of IgE synthesis by the interaction between adenosine-stimulated mast cells and B lymphocytes, and suggest that this mechanism is involved in the amplification of the allergic inflammatory responses associated with asthma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187156     DOI: 10.4049/jimmunol.172.12.7726

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

1.  Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Authors:  Sebastian Michael; Heba Abdel-Aziz; Dieter Weiser; Christa E Müller; Olaf Kelber; Karen Nieber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-10       Impact factor: 3.000

Review 2.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 3.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 4.  Adenosine receptors and asthma.

Authors:  R A Brown; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 5.  Adenosine signaling and the regulation of chronic lung disease.

Authors:  Yang Zhou; Daniel J Schneider; Michael R Blackburn
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

Review 6.  A(2B) adenosine receptors in immunity and inflammation.

Authors:  György Haskó; Balázs Csóka; Zoltán H Németh; E Sylvester Vizi; Pál Pacher
Journal:  Trends Immunol       Date:  2009-05-07       Impact factor: 16.687

7.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 8.  The role of adenosine signaling in sickle cell therapeutics.

Authors:  Joshua J Field; David G Nathan; Joel Linden
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 9.  Adenosine receptors and asthma in humans.

Authors:  C N Wilson
Journal:  Br J Pharmacol       Date:  2008-10       Impact factor: 8.739

10.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.